StockData
Amgen Inc logo

Amgen Inc

AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$465.45−0.56 (-0.12%)

Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%

Amgen EPOGEN (epoetin alfa by Quarter

EPOGEN (epoetin alfa — Dialysis Anemia, legacy standalone disclosure) — U.S. product sales ($M) ($M)

QuarterlyAnnual

Amgen EPOGEN (epoetin alfa: $19M in Q4 2024, down 65.5% from a year earlier. That is the lowest of the 32 quarters on record here. No newer figure appears in the documents we track.

Latest, Q4 2024
19
Period ended Dec 31, 2024
Change on a year earlier
-65.5%
55 in Q4 2023
History
32 quarters
Since Q1 2017
Sources
28
Documents cited below

Where the Q4 2024 figure comes from

“|| EPOGEN ® | 19 | — | 19 | 55 | (65%)”

Source: Form 8-K (amgn-20241231earningsrelea.htm, filed 2025-02-04) ↗

Reported in Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Product Sales Detail.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedEPOGEN (epoetin alfa — Dialysis Anemia, legacy standalone disclosure) — U.S. product sales ($M) ($M)Year on yearSource
Q4 2024Dec 31, 202419-65.5%Form 8-K (amgn-20241231earningsrelea.htm, filed 2025-02-04) ↗
Q3 2024Sep 30, 202433-34.0%Form 8-K (amgn-20240930earningsrelea.htm, filed 2024-10-30) ↗
Q2 2024Jun 30, 202432-47.5%Form 8-K (amgn-20240630earningsrelea.htm, filed 2024-08-06) ↗
Q1 2024Mar 31, 202441-31.7%Form 8-K (amgn-20240331earningsrelea.htm, filed 2024-05-02) ↗
Q4 2023Dec 31, 202355-51.8%Form 8-K (amgn-20231231earningsrelea.htm, filed 2024-02-06) ↗
Q3 2023Sep 30, 202350-63.2%Form 8-K (amgn-2023930earningsrelease.htm, filed 2023-10-31) ↗
Q2 2023Jun 30, 202361-55.1%Form 8-K (amgn-2023630earningsrelease.htm, filed 2023-08-03) ↗
Q1 2023Mar 31, 202360-50.0%Form 8-K (amgn-2023331earningsrelease.htm, filed 2023-04-27) ↗
Q4 2022Dec 31, 2022114-10.9%Form 8-K (amgn-20221231earningsrelea.htm, filed 2023-01-31) ↗
Q3 2022Sep 30, 2022136-1.4%Form 8-K (amgn-2022930earningsrelease.htm, filed 2022-11-03) ↗
Q2 2022Jun 30, 2022136+4.6%Form 8-K (amgn-2022630earningsrelease.htm, filed 2022-08-04) ↗
Q1 2022Mar 31, 2022120-4.0%Form 8-K (amgenq12022earningsrelease.htm, filed 2022-04-27) ↗
Q4 2021Dec 31, 2021128-3.8%Form 8-K (amgenq42021earningsrelease.htm, filed 2022-02-07) ↗
Q3 2021Sep 30, 2021138-7.4%Form 8-K (amgn-2021930xq3ex991.htm, filed 2021-11-02) ↗
Q2 2021Jun 30, 2021130-19.3%Form 8-K (amgn-2021630xq2ex991.htm, filed 2021-08-03) ↗
Q1 2021Mar 31, 2021125-19.4%Form 8-K (amgn-2021331xq1ex991.htm, filed 2021-04-27) ↗

Cite this data

StockData. (2026). Amgen EPOGEN (epoetin alfa ($M), quarterly Q1 2017–Q4 2024 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod-epogen-us

See every metric in the Amgen KPI table. Data updated Oct 28, 2026.